520 related articles for article (PubMed ID: 28818333)
21. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
[TBL] [Abstract][Full Text] [Related]
22. p53 and hereditary cancer.
Merino D; Malkin D
Subcell Biochem; 2014; 85():1-16. PubMed ID: 25201186
[TBL] [Abstract][Full Text] [Related]
23. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
24. [p53 transgenic and knockout mice].
Oda H
Nihon Rinsho; 2000 Jun; 58(6):1250-4. PubMed ID: 10879049
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome.
Talwalkar SS; Yin CC; Naeem RC; Hicks MJ; Strong LC; Abruzzo LV
Arch Pathol Lab Med; 2010 Jul; 134(7):1010-5. PubMed ID: 20586629
[TBL] [Abstract][Full Text] [Related]
26. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
27. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
28. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle arrest defect in Li-Fraumeni Syndrome: a mechanism of cancer predisposition?
Williams KJ; Boyle JM; Birch JM; Norton JD; Scott D
Oncogene; 1997 Jan; 14(3):277-82. PubMed ID: 9018113
[TBL] [Abstract][Full Text] [Related]
30. [Update on Li-Fraumeni syndrome].
Dutzmann CM; Vogel J; Kratz CP; Pajtler KW; Pfister SM; Dörgeloh BB
Pathologe; 2019 Nov; 40(6):592-599. PubMed ID: 31511974
[TBL] [Abstract][Full Text] [Related]
31. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
32. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: a review.
Soussi T; Leblanc T; Baruchel A; Schaison G
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):33-6. PubMed ID: 8511038
[TBL] [Abstract][Full Text] [Related]
34. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
35. A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome.
Id Said B; Malkin D
Cancer Genet; 2015; 208(1-2):47-51. PubMed ID: 25683625
[TBL] [Abstract][Full Text] [Related]
36. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
37. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
38. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
39. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
40. The effect of epigenetic silencing and TP53 mutation on the expression of DLL4 in human cancer stem disorder.
Yao Z; Sherif ZA
Oncotarget; 2016 Sep; 7(39):62976-62988. PubMed ID: 27542210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
